PT  - JOURNAL ARTICLE
AU  - Fabiola Atzeni
AU  - Luisa Costa
AU  - Francesco Caso
AU  - Raffaele Scarpa
AU  - Piercarlo Sarzi-Puttini
TI  - Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis
AID  - 10.3899/jrheum.150643
DP  - 2015 Nov 01
TA  - The Journal of Rheumatology
PG  - 79--81
VI  - 93
4099  - http://www.jrheum.org/content/93/79.short
4100  - http://www.jrheum.org/content/93/79.full
SO  - J Rheumatol2015 Nov 01; 93
AB  - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents.